{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:52:20Z","timestamp":1792043540869,"version":"4.4.0"},"reference-count":59,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.4161\/hv.22994","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T21:20:33Z","timestamp":1361395233000},"page":"823-833","source":"Crossref","is-referenced-by-count":10,"title":["A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France"],"prefix":"10.1080","volume":"9","author":[{"given":"Xavier","family":"Bresse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Largeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Roze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,10,27]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ejca.2009.07.019","article-title":"HPV infection in Europe","volume":"45","author":"De Vuyst","year":"2009","journal-title":"Eur J Cancer"},{"key":"R2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"R3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archotol.130.6.711","article-title":"Clinical course of recurrent respiratory papillomatosis in Danish children","volume":"130","author":"Silverberg","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6\/11 disease. Vaccine 2006;24 Suppl 3:S3\/35\u201341.","DOI":"10.1016\/j.vaccine.2006.06.015"},{"key":"R5","first-page":"671v94","article-title":"Recurrent respiratory papillomatosis","volume":"45","author":"Venkatesan","year":"2012","journal-title":"OtolaryngolClin North Am"},{"key":"R6","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"key":"R7","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1016\/j.vaccine.2010.07.007","article-title":"Sustained efficacy and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women","volume":"28","author":"De Carvalho","year":"2010","journal-title":"Vaccine"},{"key":"R8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"R9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"R10","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"R11","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"R12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"R13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"R14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol"},{"key":"R15","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"Dillner","year":"2010","journal-title":"BMJ"},{"key":"R16","unstructured":"Gardasil Summary of Product Characteristics. European Medicines Agency January 2012. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000703\/WC500021142.pdf [Last accessed June 21, 2012]"},{"key":"R17","unstructured":"World Health Organization. Weekly Epidemiological Report 27 May 2011. Available at: http:\/\/www.who.int\/wer\/2011\/wer8622.pdf [Last accessed June 21, 2012]"},{"key":"R18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2011.12.009","article-title":"Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine","volume":"53","author":"Rowhani-Rahbar","year":"2012","journal-title":"J Clin Virol"},{"key":"R19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"R20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"R21","unstructured":"Brown D. The clinical impact of cross protection to non-vaccine HPV types. Abstract (P18.13) presented at the 27th International papillomavirus conference. Berlin, Germany September 17\u201322, 2011. Available at: http:\/\/www.hpv2011.org\/pics\/1\/4\/Abstract%20Book%202%20APSC%20WEBB%20110922.pdf [Last accessed June 22, 2012]"},{"key":"R22","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2011.05.018","article-title":"Economic burden of HPV-related cancers in France","volume":"29","author":"Borget","year":"2011","journal-title":"Vaccine"},{"key":"R23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.gyobfe.2006.12.010","article-title":"[Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]","volume":"35","author":"Monson\u00e9go","year":"2007","journal-title":"Gynecol Obstet Fertil"},{"key":"R24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1258\/ijsa.2010.010073","article-title":"Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children","volume":"21","author":"Donne","year":"2010","journal-title":"Int J STD AIDS"},{"key":"R25","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1016\/j.vaccine.2011.02.064","article-title":"HPV vaccination in France: uptake, costs and issues for the National Health Insurance","volume":"29","author":"Fagot","year":"2011","journal-title":"Vaccine"},{"key":"R26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.gyobfe.2006.09.005","article-title":"[Cervical cancer screening and associated treatment costs in France]","volume":"34","author":"Bergeron","year":"2006","journal-title":"Gynecol Obstet Fertil"},{"key":"R27","doi-asserted-by":"crossref","first-page":"d5775","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"},{"key":"R28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2011.01.029","article-title":"Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles","volume":"121","author":"Capri","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R29","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"R30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"R31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S0266462307080026","article-title":"Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France","volume":"24","author":"Bergeron","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"key":"R32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00038-010-0216-6","article-title":"A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer","volume":"56","author":"Demarteau","year":"2011","journal-title":"Int J Public Health"},{"key":"R33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3111\/13696998.2010.490481","article-title":"Modelling the economic value of cross- andsustained-protection in vaccines against cervical cancer","volume":"13","author":"Demarteau","year":"2010","journal-title":"J Media Econ"},{"key":"R34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"key":"R35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R36","unstructured":"World Health Organization Expert Committee on Biological Standardization. Guidelines to assure the Quality, Safety and Efficacy of Recombinant Human Papillomavirus-like particle vaccines. Geneva, Switzerland 23\u201327 October 2006. Available at: http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/human_papillomavirus\/HPVg%20Final%20BS%202050%20.pdf [Last accessed July 20, 2012]"},{"key":"R37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurpub\/ckp141","article-title":"A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme","volume":"20","author":"Dee","year":"2010","journal-title":"Eur J Public Health"},{"key":"R38","first-page":"pii: 20274","article-title":"Updated version of ECDC Guidance on human papillomavirus vaccines in Europe available","volume":"17","year":"2012","journal-title":"Euro Surveill"},{"key":"R39","unstructured":"United Kingdom Department of Health. April 2012. Factsheet on Human Papillomavirus vaccination. Available at: http:\/\/www.dh.gov.uk\/prod_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_133346.pdf [Last accessed 01 June 2012]"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"MartyRRozeSBresseXLargeronNSmith-PalmerJ.Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. 2012","DOI":"10.1186\/1471-2407-13-10"},{"key":"R41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11591170-000000000-00000","article-title":"Economic and humanistic burden of external genital warts","volume":"30","author":"Raymakers","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"R42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/01.olq.0000253337.62932.29","article-title":"Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases","volume":"34","author":"Dempsey","year":"2007","journal-title":"Sex Transm Dis"},{"key":"R43","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"key":"R44","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Guide m\u00e9thodologique: Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique \u00e0 la HAS, October 2011. Available at: http:\/\/www.has-sante.fr\/portail\/jcms\/c_1120711\/choix-methodologiques-pour-l-evaluation-economique-a-la-has [Last accessed July 19, 2012]"},{"key":"R45","first-page":"598","article-title":"Management of anogenital warts (condylomata acuminata)","volume":"11","author":"von Krogh","year":"2001","journal-title":"Eur J Dermatol"},{"key":"R46","unstructured":"Health Protection Agency. Communicable Disease Report Weekly. Trends in anogenital warts and anogenital herpes simplex virus infection in the United Kingdom: 1996 to 2005. 2006; 16: No.48."},{"key":"R47","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0029-7844(02)03081-8","article-title":"Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis","volume":"101","author":"Silverberg","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijporl.2009.09.004","article-title":"The role of HPV type in Recurrent Respiratory Papillomatosis","volume":"74","author":"Donne","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"R49","unstructured":"Hospices civils de Lyon \/ Institut de veille Sanitaire \/ Institut national du cancer \/ Francim \/ Insititutnaitonal de la sant\u00e9 et de la recherch\u00e9m\u00e9dicale. Projections de l'incidence et de la mortalit\u00e9 par cancer en France en 2011, Rapport Technique. Juin 2011. http:\/\/www.invs.sante.fr\/surveillance\/cancers [Last accessed 06 March 2012]"},{"key":"R50","first-page":"219","article-title":"Co\u00fbt de la prise en charge du cancer invasif du col de l\u2019ut\u00e9rus en France","volume":"94","author":"Arveux","year":"2007","journal-title":"Bull Cancer"},{"key":"R51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"key":"R52","first-page":"5","article-title":"Co\u00fbt de prise en charge des cancers de la vulve et du vagin en France","volume":"28","author":"R\u00e9my","year":"2010","journal-title":"Journal d'Economie M\u00e9dicale."},{"key":"R53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.respe.2010.06.165","article-title":"Economic burden of anal cancer management in France","volume":"58","author":"Abramowitz","year":"2010","journal-title":"Rev Epidemiol Sante Publique"},{"key":"R54","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1758-3284-2-15","article-title":"Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)","volume":"2","author":"Dayyani","year":"2010","journal-title":"Head Neck Oncol"},{"key":"R56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1758-3284-2-22","article-title":"Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database","volume":"2","author":"St Guily","year":"2010","journal-title":"Head Neck Oncol"},{"key":"R57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-12-30","article-title":"Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review","volume":"12","author":"Hartwig","year":"2012","journal-title":"BMC Cancer"},{"key":"R58","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jcp.2008.063149","article-title":"Human papillomavirus prevalence and type distribution in penile carcinoma","volume":"62","author":"Miralles-Guri","year":"2009","journal-title":"J Clin Pathol"},{"key":"R59","unstructured":"R\u00e9my V, Vainchtock A. Hospitalization and management costs of patients with penile cancer in France. Poster presented at the 17th Congress of the EuropeanAcademy of Dermatology and Venerology, 17th-21st Sept. 2008, Paris, France."}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/hv.22994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T15:54:51Z","timestamp":1595433291000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.22994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,27]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.4161\/hv.22994"],"URL":"https:\/\/doi.org\/10.4161\/hv.22994","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}